The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Lomitapide
Open accessAbstract
In this series we draw attention to medicines that have entered the European market with an entirely new mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MTP facilitates the transfer and loading of triglycerides and phospholipids onto ApoB-100 in hepatic cells' endoplasmic reticulum, thereby inhibiting the assembly of very-low-density lipoprotein (VLDL) particles.
“MTP facilitates the transfer and loading of triglycerides and phospholipids onto ApoB-100 in hepatic cells’ endoplasmic reticulum. Thereby, the assembly of very-low-density lipoprotein (VLDL) particles, which turn into LDL-C after release into the blood serum, is inhibited.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [156]
The Mechanism section (page not supplied) says MTP loads triglycerides onto ApoB100 as part of VLDL assembly. Contrary to the citing sentence’s causal claim, it says inhibiting MTP—not MTP’s loading activity—blocks VLDL assembly. The passage does not specify phospholipids or the endoplasmic reticulum. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredLomitapide lowers cholesterol by inhibiting the microsomal triglyceride transfer protein (MTP).
“Lomitapide lowers cholesterol by inhibiting the microsomal triglyceride transfer protein (MTG) [155, 156].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [156]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
Raal, F. J., & Santos, R. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.019 · Cited by 349
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Primary disorders of LDL-cholesterol metabolism
Rosenson, R. S., de Ferranti, S. D., Freeman, M. W., & Saperia, G. M. (2011) · Cited by 1
Flagged first, then by citations
Cited by
Sorted by citations
Mhaimeed, O., Burney, Z. A., Schott, S. L., Kohli, P., Marvel, F. A., & Martin, S. S. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100649 · Cited by 140
Giacomini, I., Gianfanti, F., Desbats, M. A., Orso, G., Berretta, M., Prayer‐Galetti, T., Ragazzi, E., & Cocetta, V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682911 · Cited by 121
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Lomitapide for the treatment of hypercholesterolemia
Berberich, A. J., & Hegele, R. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340941 · Cited by 77
Iqbal, Z., Ho, J. H., Adam, S., France, M. W., Syed, A. A., Neely, D., Rees, A., Khatib, R., Cegla, J., Byrne, C. D., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.008 · Cited by 64
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 63
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52
Zuo, Q., Liao, L., Yao, Z.-T., Liu, Y.-P., Wang, D.-K., Li, S., Yin, X., He, Q., & Xu, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.010 · Cited by 43
Sen, P., Kandasamy, T., & Ghosh, S. S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110529 · Cited by 31
Lomitapide for the treatment of hypertriglyceridemia
Berberich, A. J., & Hegele, R. A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254187 · Cited by 29
Efficacy and Safety of Lomitapide in Hypercholesterolemia
Liu, X., Men, P., Wang, Y., Zhai, S., Zhao, Z., & Liu, C. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0214-7 · Cited by 26
Kypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G. D., & Constantinou, C. (2018) · Angiology · doi:10.1177/0003319718779533 · Cited by 26
Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites
de Sousa, A. C. C., Maepa, K., Combrinck, J. M., & Egan, T. J. (2020) · Molecules · doi:10.3390/molecules25071571 · Cited by 24
Yasuda, D., Torii, H., Shimizu, R., Hiraoka, Y., & Kume, N. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00338 · Cited by 19
Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review
Neef, D., Berthold, H. K., & Gouni‐Berthold, I. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1162095 · Cited by 17
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 16
Leggiero, E., Labruna, G., Iaffaldano, L., Lombardo, B., Greco, A., Fiorenza, D., Gramanzini, M., Montanaro, D., Baldi, A., Cerullo, V., et al. (2019) · Gene Therapy · doi:10.1038/s41434-019-0061-z · Cited by 15
Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 14
Drug-drug interactions when treating HIV-related metabolic disorders
Gutiérrez, M. D. M., Mateo, G. M., Corbacho, N., Vidal, F., & Domingo, P. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1667334 · Cited by 14
Fan, N., Zhao, F., Meng, Y., Chen, L., Miao, L., Wang, P., Tang, M., Wu, X., Li, Y., Li, Y., et al. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114467 · Cited by 11
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism
Huang, J., Guo, B., Lin, F., Zeng, L.-M., Wang, T., Dang, X.-Y., Yang, Y., Hu, Y., Liu, J., & Wang, H. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105683 · Cited by 8
Munkhsaikhan, U., Kwon, Y., Sahyoun, A. M., Ait‐Aissa, K., Kassan, A., & Kassan, M. (2022) · Obesity · doi:10.1002/oby.23389 · Cited by 8
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac104.026032 · Cited by 6
Khan, M. A., Singh, G. K., Abrar, S., Ganeshan, R., Morgan, K., & Harky, A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1960311 · Cited by 4
Lomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma
Ivanova, A., Wilson, T. M., Ghannad‐Zadeh, K., Tse, E., Flick, R., Wu, M., & Das, S. (2025) · JCI Insight · doi:10.1172/jci.insight.186703 · Cited by 3
Significance of traditional herbal medicine for dyslipidemia.
Kang, Y., Kim, Y.-J., & Kim, K. (2023) · PubMed Central · Cited by 3
Natural Antioxidants in Obesity and Related Diseases
Kim, H. I., & Park, J. (2023) · Antioxidants · doi:10.3390/antiox12111966 · Cited by 3
The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr−/− Mice with Obesity
Munkhsaikhan, U., Kwon, Y. I., Sahyoun, A. M., Galán, M., González, A. A., Ait‐Aissa, K., Abidi, A. H., Kassan, A., & Kassan, M. (2023) · Antioxidants · doi:10.3390/antiox12061287 · Cited by 2
Dziewierz, A., Bobrowska, B., Streb, W., Pelliccia, F., Bartuś, S., & Rajtar-Salwa, R. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2570839
Metadata
- Authors
- Goulooze, S. C., Cohen, A. F., & Rissmann, R.
- Affiliations
- Centre for Human Drug Research (NL)
- Leiden University Medical Center (NL)
- Corresponding author
- Rissmann, Robert
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2015-07-02
- Volume
- 80
- Issue
- 2
- Pages
- 179-181
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC4541964
- OpenAlex
- W2317892310
- Semantic Scholar
- 5452823a0a50cd8781bc54c8b6ac2e394e957e33
- Cited by
- 29
- References
- 3
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lomitapide, novel mechanism of action, drug approval, European market entry, cholesterol absorption inhibition, hypercholesterolemia
- MeSH terms
- Anticholesteremic Agents, Benzimidazoles, Carrier Proteins, Fatty Acids, Nonesterified, Homozygote, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Liver Function Tests, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
